Inovio Pharmaceuticals to Present at Scientific Conferences
Sep 7, 2011
BLUE BELL, Pa., Sept. 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that scientists, advisors and collaborators of the company will make presentations at multiple scientific conferences:
AIDS Vaccine Conference
Bangkok Convention Centre at CentralWorld
Stanley Plotkin, University of Pennsylvania; Scientific Advisor, Inovio
"Are there lessons from past vaccines for an AIDS vaccine?"
September 12, 2011
Jeffrey Currier, United States Military HIV Research Program; Inovio collaborator
"Cell-mediated immune responses after DNA delivered by either Biojector or electroporation and boosted with a heterologous insert recombinant poxvirus"
September 13, 2011
Jean Boyer, University of Pennsylvania; Inovio collaborator
"Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of Rhesus macaques immunized with an SIV DNA vaccine"
September 14, 2011
Gene Vaccination in Cancer
Ascoli Piceno, Italy
Palazzo dei Capitani, Piazza del Popolo
Amir Khan, Ph.D., Director of Product Development, Inovio
"Development of DNA vaccines for cancer delivered by electroporation"
September 16, 2011
Mark Bagarazzi, MD, Chief Medical Officer, Inovio
"HPV16 and HPV18 E6 and E7 SynCon® DNA vaccines elicit robust T-cell and antibody responses after electroporation-mediated delivery: Potential to treat cervical dysplasia and cancer"
September 17, 2011
Phacilitate – Vaccine Forum Singapore 2011
The Marina Bay Sands Hotel
Dr. J. Joseph Kim, Ph.D., President & CEO, Inovio
"Launching higher priced products in Asia: Experiences so far with rotavirus, HPV, RSV and pneumococcal conjugate vaccines"
September 20, 2011
Dr. J. Joseph Kim, Ph.D., President & CEO, Inovio
"HCV and HPV: How enhanced DNA vaccines are developed as therapeutic vaccines for major chronic infectious diseases and cancer: Generation of best-in-class T cell immune responses by in-vivo electroporation delivery"
September 21, 2011
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon® vaccines are designed to provide broad cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
* * *
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended June 30, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
SOURCE Inovio Pharmaceuticals, Inc.